CFDE Data Portal | Search ZNF337-AS1

	Label	Description
	ZNF337-AS1 Gene (Entity type)	ENSG00000213742 - ZNF337 antisense RNA 1
	GSE130401 4 V 3 TRAMETINIB HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE214931 temozolomide 4 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE236896 GSE237665 DNMT EZH2 inhibition 1 v 5 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE171177,GSE171181 1 V 0 E7107 HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE119007 prostaglandin TS-A clone E2 1 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE119369 H10 inhibition 3 v 7 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE108464 AZ-628 6 v 15 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE146358 dopamine 5 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE128076 doxycycline HEK293 1 v 3 human dn Gene Set (Entity type)	A Gene Set from LINCS

ZNF337-AS1

ENSG00000213742 - ZNF337 antisense RNA 1

GSE130401 4 V 3 TRAMETINIB HUMAN DN

A Gene Set from LINCS

GSE214931 temozolomide 4 v 0 human up

A Gene Set from LINCS

GSE236896 GSE237665 DNMT EZH2 inhibition 1 v 5 human dn

A Gene Set from LINCS

GSE171177,GSE171181 1 V 0 E7107 HUMAN UP

A Gene Set from LINCS

GSE119007 prostaglandin TS-A clone E2 1 v 0 human dn

A Gene Set from LINCS

GSE119369 H10 inhibition 3 v 7 human dn

A Gene Set from LINCS

GSE108464 AZ-628 6 v 15 human dn

A Gene Set from LINCS

GSE146358 dopamine 5 v 2 human up

A Gene Set from LINCS

GSE128076 doxycycline HEK293 1 v 3 human dn

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.